Cas:29582-31-8 (4-ethoxybenzoyl)-3-acrylic acid manufacturer & supplier

Chemical Name:(4-ethoxybenzoyl)-3-acrylic acid

CAS.NO:29582-31-8

Synonyms:MFCD00075337;trans-(4-Ethoxybenzoyl)-3-acrylic acid

Molecular Formula:C₁₂H₁₂O₄

Molecular Weight:220.22100

HS Code:2918990090

Physical and Chemical Properties:

Melting point:140-144ºC

Boiling point:398.2ºC at 760mmHg

Density:1.205g/cm3

Index of Refraction:

PSA:63.60000

Exact Mass:220.07400

LogP:1.90880

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like MFCD00075337 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,trans-(4-Ethoxybenzoyl)-3-acrylic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD00075337 Use and application,trans-(4-Ethoxybenzoyl)-3-acrylic acid technical grade,usp/ep/jp grade.

Related News: The patient, who arrived from Wuhan, is ��stable and under medical care,�� the ministry said in a statement, adding there is ��no cause for concern�� for the public. (4-ethoxybenzoyl)-3-acrylic acid manufacturer This also includes its anti-tau pipeline, with the FDA’s approval having “implications for AD programmes targeting Tau,” according to Jefferies. (4-ethoxybenzoyl)-3-acrylic acid supplier Beta Bionics is pursuing regulatory approval of its insulin-only bionic pancreas, followed by its dual-hormone system, which will also administer a glucagon analog in order to raise blood-sugar levels without the need to consume carbohydrates. Beta Bionics operates in Massachusetts and California. (4-ethoxybenzoyl)-3-acrylic acid vendor The patient, who arrived from Wuhan, is ��stable and under medical care,�� the ministry said in a statement, adding there is ��no cause for concern�� for the public. (4-ethoxybenzoyl)-3-acrylic acid factory During analysis of the clinical trial data, the researchers realized that about a third of the participants had low levels of abnormal tau protein, which makes them not very suitable for evaluating the effects of a treatment halting the progression of tau pathology.